LekoskopLekoskop
EN All changes
Medicine recalls and shortages › New approvals › 7 May 2026
MHRA approval

donidalorsen (Dawnzera)

Published on 7 May 2026 · source: MHRA — Medicines and Healthcare products Regulatory Agency
MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema
MHRA announcement ↗ All events: donidalorsen (Dawnzera)

What this means

The MHRA has announced the approval of a medicine or a new indication in the UK. Approval does not mean the product is already available on the NHS: NICE appraisal and commissioning may follow.

Summary

MHRA approves donidalorsen (Dawnzera) for the treatment of hereditary angioedema

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.